

Redefining Care for HR-Positive Metastatic Breast Cancer

How to Navigate Critical Decision Points

MONDAY, 16 SEPTEMBER 2024 | 18:30–20:00 CEST

VALENCIA AUDITORIUM, HALL 5, FIRA BARCELONA GRAN VIA, BARCELONA, SPAIN

MODERATOR



Javier Cortés, MD, PhD
Head
International Breast Cancer Center, IBCC
Barcelona
Head
IOB Madrid, Institute of Oncology
Madrid, Spain

PANELISTS



Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational
Research Integration
UCLA Health Jonsson Comprehensive
Cancer Center
Los Angeles, California, United States



Sibylle Loibl, MD, PhD
Chair
German Breast Group
Professor
Goethe University Frankfurt
Clinical Consultant
Centre for Haematology
and Oncology, Bethanien
Frankfurt, Germany



Paolo Tarantino, MD
Advanced Research Fellow
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts, United States

AGENDA

18:30

Welcome and Introduction
Javier Cortés, MD, PhD

18:40

***New Frontiers in Estrogen
Receptor Inhibition***
Sibylle Loibl, MD, PhD

18:50

***Novel Approaches to Targeting
the PI3K/AKT/mTOR Pathway***
Javier Cortés, MD, PhD

19:05

***Latest Insights on ADCs for HR-Positive
/HER2-Negative Metastatic Breast Cancer***
Aditya Bardia, MD, MPH, FASCO

19:20

***Latest Insights on ADCs for HR-Positive,
HER2-low Metastatic Breast Cancer***
Paolo Tarantino, MD

19:35

***In the Hot Seat: Common Clinical
Queries with ADCs***
All Speakers

19:45

Experts' Key Takeaways from ESMO 2024
All Speakers

19:50

Audience Q&A and Close
Javier Cortés, MD, PhD

Medscape Global Oncology